OSE Immunotherapeutics – equity proposition

OSE Immunotherapeutics — 5 videos in collection

More on this equity

OSE Immunotherapeutics (PAR:OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange.

There are five key reasons why OSE may be considered an attractive investment.

OSE has a diverse pipeline of assets, backed by science at the forefront of immunotherapy research, offering multiple shots at goal.
OSE has a track record of partnering with pharma players.
OSE is a platform company with four cutting-edge preclinical platforms offering broad potential to create a diverse pipeline of first-in-class therapies with a host of applications.
The company is led by a highly experienced executive leadership team with a proven track record in drug development and business execution.
OSE has a robust financial position and an attractive outlook for growth.

If you would like to learn more about OSE Immunotherapeutics, please see our latest research here.

< Previous

Healthcare

26.03.25

Healthcare

11.06.24

Get access to the very latest content matched to your personal investment style.

Equities